-
Opthea IPO: What Investors Should Know About The Genentech, Regeneron Challenger
Thursday, October 15, 2020 - 4:15pm | 696Read More...Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea Ltd (NASDAQ: OPT) is wet age-related macular degeneration, commonly referred to as AMD, and other...
-
IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week
Sunday, October 11, 2020 - 1:52pm | 1239Read More...This week could see up to nine companies price their IPOs. Here is a look at the companies looking to go public this week. Codiak Biosciences: Clinical stage biopharmaceutical Codiak Biosciences (NASDAQ: CDAK) plans to sell 5.5 million shares at a price point of $14 to $16. The...
-
Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar
Thursday, October 3, 2019 - 3:49pm | 1635Read More...Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value...
-
In Honor Of Friday The 13th, Here Are Some Of The Unluckiest Trades Of 2016
Friday, January 13, 2017 - 9:50am | 657Read More..."Paraskavedekatriaphobia" — Ever heard of it? This phobia concerns fear of Friday the 13th. The day has been considered unlucky since time immemorial. There have been different explanations for why the day is unlucky, although the oft-mentioned reason is Jesus being with 12 of his disciples (...
-
Which Wet AMD Stock Would You Buy Right Now?
Wednesday, December 14, 2016 - 12:30pm | 441Read More...Shares of Ophthotech Corp (NASDAQ: OPHT) tanked more than 80 percent on Monday after the company announced that the primary endpoint in two Phase 3 trials exploring its Fovista® therapy was not met. Fovista is Ophthotech's therapy intended to be administered in combination with an anti VEGF agent...
-
Imprimis CEO Talks Phenomenal Quarter: 'Shocking' Statistics, Simplification And A Trifecta For Success
Thursday, December 1, 2016 - 1:03pm | 510Read More...Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) is a San Diego-based small-cap pharmaceutical company that specializes in the ophthalmology space. The company is coming off an impressive 81 percent year-over-year increase in revenues in its most recent quarter and clocked nearly a 20 percent...
-
Egalet Vs. Ophthotech: Battle Of The December Binary Trades
Monday, November 28, 2016 - 2:51pm | 574Read More...Egalet Corp (NASDAQ: EGLT) and Ophthotech Corp (NASDAQ: OPHT) have catalysts coming up before the end of the year that can bring glory or spell doom for these companies. Upcoming Catalysts The former is awaiting FDA decision on ARYMO ER, its lead drug candidate, which is an abuse-deterrent...
-
OHR Pharmaceutical Gains 7% Following Agreement With FDA
Tuesday, March 29, 2016 - 9:05am | 190Read More...Shares of OHR Pharmaceutical Inc (NASDAQ: OHRP), a nano-cap pharmaceutical company that focuses on the treatment of ocular diseases, spiked higher by more than 7 percent early Tuesday morning. OHR Pharmaceutical announced it has reached an agreement on the Special Protocol Assessment (SPA) with the...
-
Why Avalanche Biotechnologies Is Coming Off A Big Day
Thursday, June 11, 2015 - 9:10am | 340Read More...Shares of Avalanche Biotechnologies Inc (NASDAQ: AAVL) closed up more than 7 percent on Wednesday following positive commentary by TheStreet.com. According to author Alfredo Fontanini, the company is approaching an important clinical trial catalyst. Results from a phase IIa study of Avalanche's...
-
Pfenex Inc. In Development Pact For Macular Degeneration Drug
Tuesday, February 10, 2015 - 1:07pm | 205Read More...Pfenex Inc (NYSE: PFNX) shares gained more than 20 percent after the company disclosed its macular degeneration drug candidate will get collaborative support from Hospira, Inc. (NYSE: HSP). San Diego-based Pfenex changed hands recently at $8.25, up $1.35. The drug under development is aimed at...
-
RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis
Thursday, April 24, 2014 - 4:31pm | 216Read More...RBC Capital Markets analyst Adnan Butt is optimistic on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) following lower sales outside the US by competing Novartis AG (NYSE: NVS) drug Lucentis. Lucentis, is a ranibizumab injection for the treatment of wet age-related macular degeneration...
-
JP Morgan Comments on Wet AMD Data for Regeneron
Wednesday, June 13, 2012 - 9:41am | 245Read More...JP Morgan has published a research report on Regeneron Pharmaceuticals (NASDAQ: REGN) after wet AMD data was released on the company's Lucentis and Opththotech's Fovista. In the report, JP Morgan writes, "Today, competitive data in the wet AMD (Age-related Macular Degeneration) space was released...
